Fusion immunomodulatory proteins and methods for making same
AssigneeBiocon Limited
InventorsNAGARAJ GOVINDAPPA, MARIA MELINA SOARES, KEDERNATH SASTRY
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGFβRII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.
Claims2
A fusion protein comprising a targeting moiety and an immunomodulating moiety exhibiting bi-specificiity, wherein the targeting moiety and the immunomodulating moiety are linked by an amino acid spacer encoded by nucleotide sequence SEQ ID NO:
- 4, wherein the immunomodulating moiety is encoded by nucleotide sequence SEQ ID NO:
- 3 or SEQ ID NO:
- 7, wherein the targeting moiety is an anti-EGFR1 antibody encoded by nucleotide sequences consisting of SEQ ID NO:
- 1 and SEQ ID NO:
- 2, wherein the encoded by nucleotide sequence SEQ ID NO:
- 3 or SEQ ID NO:
- 7 is attached via SEQ ID NO:
- 4 to the C-terminus of SEQ ID NO 1 or SEQ ID NO:
- 2.
A fusion protein comprising a targeting moiety and an immunomodulating moiety exhibiting bi-specificiity, wherein the targeting moiety and the immunomodulating moiety are linked by an amino acid spacer encoded by nucleotide sequence SEQ ID NO:
- 4, wherein the immunomodulating moiety is encoded by nucleotide sequence SEQ ID NO:
- 3 or SEQ ID NO:
- 7, wherein the targeting moiety is an anti-EGFR1 antibody encoded by nucleotide sequences consisting of SEQ ID NO:
- 5 and SEQ ID NO:
- 6, wherein the encoded by nucleotide sequence SEQ ID NO:
- 3 or SEQ ID NO:
- 7 is attached via SEQ ID NO:
- 4 to the C-terminus of SEQ ID NO 5 or SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.